Evidence map›Paper›PMID 26461001›Full record

ArticleInternational journal of radiation oncology, biology, physics2015

Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.

Nathan A Koonce, Charles M Quick, Matthew E Hardee, Azemat Jamshidi-Parsian, Judith A Dent, Giulio F Paciotti, Dmitry Nedosekin, Ruud P M Dings, Robert J Griffin

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Nano-biotechnology in tumour and cancerous disease: A perspective review.Journal of cellular and molecular medicine · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Nanogold Functionalized With Lipoamide-Frontiers in chemistry · 2021
    Article
  13. Review
  14. Review
  15. Gold Nanoparticles as Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Nathan A KoonceDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Charles M QuickDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Matthew E HardeeDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Azemat Jamshidi-ParsianDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Judith A DentDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Giulio F PaciottiCytImmune Sciences, Rockville, Maryland.
Dmitry NedosekinDepartment of Otolaryngology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Ruud P M DingsDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Robert J GriffinDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address: RJGriffin@uams.edu.
University of Arkansas for Medical Sciences · USCytImmune (United States) · US

Funding

PHYSIOLOGICAL FACTORS IN HYPERTHERMIAR01CA044114 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI GRIFFIN, ROBERT JAMES · 1987 to 2012
$3.3M
NCI NIH HHS CA44114NCI NIH HHS R01 CA044114
6 · The paper itself

Abstract

purposeAlthough remarkable preclinical antitumor effects have been shown for tumor necrosis factor-α (TNF) alone and combined with radiation, its clinical use has been hindered by systemic dose-limiting toxicities. We investigated the physiological and antitumor effects of radiation therapy combined with the novel nanomedicine CYT-6091, a 27-nm average-diameter polyethylene glycol-TNF-coated gold nanoparticle, which recently passed through phase 1 trials. METHODS AND MATERIALS: The physiologic and antitumor effects of single and fractionated radiation combined with CYT-6091 were studied in the murine 4T1 breast carcinoma and SCCVII head and neck tumor squamous cell carcinoma models.

resultsIn the 4T1 murine breast tumor model, we observed a significant reduction in the tumor interstitial fluid pressure (IFP) 24 hours after CYT-6091 alone and combined with a radiation dose of 12 Gy (P<.05 vs control). In contrast, radiation alone (12 Gy) had a negligible effect on the IFP. In the SCCVII head and neck tumor model, the baseline IFP was not markedly elevated, and little additional change occurred in the IFP after single-dose radiation or combined therapy (P>.05 vs control) despite extensive vascular damage observed. The IFP reduction in the 4T1 model was also associated with marked vascular damage and extravasation of red blood cells into the tumor interstitium. A sustained reduction in tumor cell density was observed in the combined therapy group compared with all other groups (P<.05). Finally, we observed a more than twofold delay in tumor growth when CYT-6091 was combined with a single 20-Gy radiation dose-notably, irrespective of the treatment sequence. Moreover, when hypofractionated radiation (12 Gy × 3) was applied with CYT-6091 treatment, a more than five-fold growth delay was observed in the combined treatment group of both tumor models and determined to be synergistic.

conclusionsOur results have demonstrated that TNF-labeled gold nanoparticles combined with single or fractionated high-dose radiation therapy is effective in reducing IFP and tumor growth and shows promise for clinical translation.

Indexed as

AnimalsBlood VesselsCarcinoma, Squamous CellCell CountCell HypoxiaCombined Modality TherapyDisease Models, AnimalDrug Evaluation, PreclinicalExtracellular FluidFemaleGoldHead and Neck NeoplasmsMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CNanoparticlesCYT-6091GoldPolyethylene GlycolsTumor Necrosis Factor-alpha

Identifiers

PMID26461001
PMCPMC4934370
OpenAlexW2132982141

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.